Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AG-1749
Lansoprazole · 5 trials · 7 indications
The number of participants that developed gastric ulcer and/or duodenal ulcer at month 24 or final visit. Ulcers are defined as mucosal defect with white coating 3 mm or greater.
| Arm | Type | Description |
|---|---|---|
| Lansoprazole 15 mg QD | EXPERIMENTAL | - |
| Gefarnate 50 mg BID | ACTIVE_COMPARATOR | - |
| Lansoprazole 30 mg QD + Naproxen 500 mg BID | EXPERIMENTAL | (and added aspirin) |
| Celecoxib 200 mg QD | ACTIVE_COMPARATOR | (and added aspirin) |
| Lansoprazole IV 30 mg QD | EXPERIMENTAL | - |
| Lansoprazole Capsule 30 mg QD | ACTIVE_COMPARATOR | - |
| Lansoprazole 0.5 mg/kg QD | EXPERIMENTAL | - |
| Lansoprazole 1.0 mg/kg QD | EXPERIMENTAL | - |
| Lansoprazole 2.0 mg/kg QD | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Lansoprazole | DRUG | Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months. |
| Gefarnate | DRUG | Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months. |
| Lansoprazole and naproxen and aspirin | DRUG | Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks. |
| Celecoxib and aspirin | DRUG | Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks. |
Inclusion Criteria: * The patient was on nonsteroid anti-inflammatory drug (NSAID) treatment on the day when consent was obtained, and requires the long-term continuous treatment even after treatment with the investigational drug is started. * The patient was confirmed to have a history of gastric ...
Top 5 of 14 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Eloralintide, LY3016859, LY3556050, LY3526318 |
| Pacira Biosciences, Inc. | PCRX | 4 | PHASE3 | ZILRETTA, Enekinragene Inzadenovec, FX201 |
| Novo Nordisk A/S Sponsored ADR Class B | NVO | 2 | PHASE3 | NNC0487-0111 |
| Bioventus, Inc. Class A | BVS | 1 | PHASE2 | PTP-001 |
| Enlivex Ltd. | ENLV | 2 | PHASE1 | Allocetra |
Lansoprazole is used to treat acid-related gastrointestinal conditions, including esophagitis, gastroesophageal reflux disease, stomach ulcer, and duodenal ulcer. It is also studied in patients with osteoarthritis who take nonsteroidal anti-inflammatory drugs or low dose aspirin, where it is used to prevent or treat gastric and duodenal ulcers.
Lansoprazole targets ATP4A and ATP4B, the subunits of the gastric proton pump, and acts as an inhibitor of this target. By inhibiting the proton pump, lansoprazole reduces gastric acid secretion, which underlies its use in esophagitis, gastroesophageal reflux disease, and peptic ulcer disease.
Lansoprazole is developed by Takeda Pharmaceutical Company Limited, which trades under the ticker TAK. Takeda is the company associated with the clinical development program for lansoprazole across its gastrointestinal and osteoarthritis-related indications.
Lansoprazole is in Phase 2 development for its current program. It is an investigational small molecule, and the clinical trials supporting this program include Phase 1, Phase 2, and Phase 3 studies, all of which have been completed.
Lansoprazole has been studied in completed trials including NCT00787254 in gastric and duodenal ulcers in patients taking nonsteroidal anti-inflammatory drugs, NCT00220818 in infants with gastroesophageal reflux disease, NCT00175045 comparing intravenous and oral lansoprazole in erosive esophagitis, and NCT00175032 in osteoarthritis with low dose aspirin.